Latest News
Clinical Trial to Test Mekinist as Combo Therapy in Advanced Colorectal Cancer Patients
Jun 09, 2017
The MEK inhibitor Mekinist (trametinib) is to be tested in combination with Opdivo (nivolumab) — or Opdivo plus Yervoy (ipilimumab) — in colorectal cancer patients with microsatellite stable tumors under a clinical collaboration between Novartis and Bristol-Myers Squibb.
« More
- (Jun-09) - Flaws in a tumor’s genetic mending kit drive treatment response to immunotherapy
- (Jun-07) - Certain Colon Cancer Patients May Need a Shorter Chemotherapy Course, International Study Finds
- (Jun-05) - Simple way to boost cancer survival rates: diet and exercise, studies say
- (Jun-04) - Quickly reporting cancer complications may boost survival: study
- (Jun-04) - Much shorter chemo works for many colon cancer patients, study says
- (Jun-01) - Binimetinib Triple Combo to Be Tested in Microsatellite Stable Colorectal Cancer Patients
- (Jun-01) - Research and clinical trials in Texas help to combat rising rates of colon cancer among younger adults
- (May-31) - PCM-075 Proves Safe as Treatment for Colon, Other Cancer Types, Phase 1 Trial Shows
- News Archives...
|
|
|
 |
 |
 |
Twitter |
Blog |
Youtube |
Donate |
